Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, is announcing a new patent that has just been approved for the United States (no. 9187418), along with two other similar patents for Mexico (no. 222939) and Eurasia[1] (no. 021612).
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2016/01/QGC_CP_QGC001-Brevet-US-Manufacturing_20012016_VDEF_EN.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]
